贝叶斯基因组全方位TWAS与脑和血液组织的参考转录组数据一起确定了141个阿尔茨海默病痴呆症风险基因
Shuyi Guo1,2, Jingjing Yang3
1Center for Computational and Quantitative Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Alzheimer's research & therapy
|June 2, 2024
概括
贝叶斯基因组全方位TWAS (BGW-TWAS) 通过整合来自大脑和血液的cis-和trans-eQTL数据,确定了141个阿尔茨海默病 (AD) 风险基因. 这提高了对AD遗传学和潜在治疗点的理解.
科学领域:
- 遗传学 是一个遗传学.
- 基因组学就是基因组学.
- 神经科学是一个神经科学.
背景情况:
- 全转录组关联研究 (TWAS) 通过基因表达识别与疾病相关的基因.
- 对于阿尔茨海默病 (AD) 现有的TWAS通常将分析限制在cis-eQTLs上.
- 需要将cis-和trans-eQTL纳入全面的AD基因发现.
研究的目的:
- 应用贝叶斯基因组全方位TWAS (BGW-TWAS),整合来自大脑和血液组织的cis-和trans-eQTL.
- 为了提高与阿尔茨海默病 (AD) 痴呆相关的风险基因的映射.
- 识别导致AD病变的新型遗传因素.
主要方法:
- 使用贝叶斯基因组全方位TWAS (BGW-TWAS) 方法.
- 来自GTEx V8 (前额叶皮层,皮层,全血) 的综合cis-和trans-eQTL数据与AD GWAS总结统计数据.
- 采用聚合的考奇关联测试来结合不同组织的结果.
主要成果:
- 确定了141个重要的AD痴呆症TWAS风险基因.
- 发现了34个基因,主要通过跨eQTL效应联系在一起.
- 发现了之前在GWAS目录中绘制的35个基因,并检测了与AD相关的功能集群和丰富的表型.
结论:
- BGW-TWAS成功地整合了cis-和trans-eQTL数据,以识别141个AD风险基因.
- 这些发现为AD的生物机制提供了新的见解.
- 鉴定的基因代表了未来AD治疗开发的潜在目标.
更多相关视频
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.0K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
01:11Genome-wide Association Studies-GWAS
13.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.3K
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462